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Literature Review1
Flavonoids as an Intervention for
Alzheimer’s Disease: Progress and Hurdles
Towards Defining a Mechanism of Action
2
3
4
Katriona L. Hole and Robert J. Williams*5
Centre for Regenerative Medicine, Department of Biology and Biochemistry, University of Bath, UK6
Abstract. Attempts to develop a disease modifying intervention for Alzheimer’s disease (AD) through targeting amyloid
 (A) have so far been unsuccessful. There is, therefore, a need for novel therapeutics against alternative targets coupled
with approaches which may be suitable for early and sustained use likely required for AD prevention. Numerous in vitro
and in vivo studies have shown that flavonoids can act within processes and pathways relevant to AD, such as A and tau
pathology, increases in BDNF, inflammation, oxidative stress and neurogenesis. However, the therapeutic development of
flavonoids has been hindered by an ongoing lack of clear mechanistic data that fully takes into consideration metabolism
and bioavailability of flavonoids in vivo. With a focus on studies that incorporate these considerations into their experimental
design, this review will evaluate the evidence for developing specific flavonoids as therapeutics for AD. Given the current
lack of success of anti-A targeting therapeutics, particular attention will be given to flavonoid-mediated regulation of tau
phosphorylation and aggregation, where there is a comparable lack of study. Reflecting on this evidence, the obstacles that
prevent therapeutic development of flavonoids will be examined. Finally, the significance of recent advances in flavonoid
metabolomics, modifications and influence of the microbiome on the therapeutic capacity of flavonoids in AD are explored.
By highlighting the potential of flavonoids to target multiple aspects of AD pathology, as well as considering the hurdles,
this review aims to promote the efficient and effective identification of flavonoid-based approaches that have potential as
therapeutic interventions for AD.
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ALZHEIMER’S DISEASE: THE NEED FOR24
NOVEL THERAPEUTICS25
At the time of writing, there are at least 50 million26
people living with dementia worldwide [1]. Due to27
increasing life expectancies, this is predicted to triple28
by 2050, and yet there are still no therapeutics capable29
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Tel.: +44 (0)1225 386553; E-mail: r.j.williams@bath.ac.uk.
of preventing or slowing the onset of dementia. The 30
most common cause of dementia, Alzheimer’s dis- 31
ease (AD), is a neurodegenerative disease that is 32
traditionally characterized by deposition of amyloid 33
plaques and neurofibrillary tangles (NFTs), caused by 34
amyloid  peptide (A) and tau aggregation respec- 35
tively. More recently, chronic neuroinflammation and 36
gliosis have joined plaques and tangles as hallmarks 37
of AD. One of the major obstacles to preventing AD 38
progression is that by the time a clinical diagnosis 39
has been given, irreversible brain atrophy has already 40
ISSN 2213-6304/20/$35.00 © 2020 – IOS Press and the authors. All rights reserved
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occurred (Fig. 1), and pathological cascades are well41
developed.42
Theamyloid cascade hypothesis (ACH) postulates43
that it is the accumulation of A oligomers that44
initiates a downstream cascade causing neuroinflam-45
mation, tau-induced toxicity, synaptic dysfunction46
and neuronal loss [2]. Support for this hypothe-47
sis comes from the identification that mutations in48
the amyloid precursor protein (APP), presenilin-149
(PS1) [3, 4] and presenilin-2 (PS2) [5, 6], which50
either enhance the accumulation of A or promote51
an increased ratio of the longer, more aggregation52
prone A1–42 over A1–40 [7–9], are sufficient to53
cause early onset familial AD (FAD) [10]. APP can54
be processed in either a non-amyloidogenic path-55
way, driven by the -secretase enzyme ADAM10,56
or in a pro-amyloidogenic pathway involving the57
-secretase enzyme BACE1.Following cleavage by58
either of these enzymes, there is a second cleav-59
age event by -secretase which yields either p360
(non-amyloidogenic) or A (pro-amyloidogenic)61
(Fig. 1A). Presenilin forms the catalytic subunit of62
the -secretase enzyme complex [11]. According to63
the ACH, the failure to clear A1–42 initiates conse-64
quent pathological pathways that lead to the onset of65
dementia [2]. This hypothesis has been the foundation66
for the development of many A-targeting therapeu-67
tics, with the idea that by targeting this initial A68
accumulation, the resulting toxic pathways can be69
inhibited.70
Disappointingly, therapeutics targeting APP pro-71
cessing directly, such as BACE1 inhibitors, have72
failed at Phase III [12], likely due to off target effects73
[13]. Moreover, methods to reduce soluble and/or74
aggregated forms of A via antibody strategies have75
had disappointing outcomes [14, 15], although, it76
should be noted that recent reports claim that the77
A-targeting antibody Aducanumab meets its pri-78
mary endpoint. It is becoming increasingly clear that79
reducing the levels of A in the brain is unlikely to80
provide significant clinical benefit when delivered at81
the stage of mild cognitive impairment (MCI) or later.82
It is likely that, in order to be maximally effective,83
the use of A-targeting therapeutics will be required84
from the start of, and throughout, the long prodromal85
phase of AD. This limitation necessitates a strategic86
shift, either switching attention to targets that corre-87
late better with later stage disease progression, such88
as neuroinflammation or tau, or sticking with the89
existing targets but putting the focus on biomarker90
development to enable better patient stratification91
for earlier intervention. An additional approach is to92
identify and validate safe and cost-effective lifestyle 93
interventions which could be widely implemented 94
throughout mid-life to reduce AD risk at a population 95
level. 96
Flavonoid rich diets: Impact on cognitive decline 97
and AD 98
Epidemiology has long suggested that diets rich in 99
polyphenols, such as the Mediterranean diet, might 100
slow age-related cognitive decline and some studies 101
indicate reduced risk of dementia [16, 17]. Moreover, 102
consumption of flavonoids, a large family of dietary 103
polyphenol compounds, decreases cognitive decline 104
with aging [18, 19]. Although direct evidence of a 105
reduction in AD is lacking, the available epidemio- 106
logical data does suggest that flavonoid consumption 107
has the potential to ameliorate AD pathology and 108
provide symptomatic benefit. 109
There are more than 5000 types of flavonoid, and 110
they are found almost ubiquitously in plants and 111
thus are widely available in the human diet. The 112
six main subclasses of flavonoids are: anthocyani- 113
dins, flavones, isoflavones, flavonols, flavanones, and 114
flavan-3-ols (flavanols) (Fig. 2). While flavonoids 115
are well known for their ability to act as antiox- 116
idants, it is clear that they are also capable of 117
regulating intracellular responses principally through 118
modulation of protein kinase signalling pathways 119
[20]. Furthermore, there is now a substantial and 120
growing body of evidence supporting the ability 121
of flavonoids to interfere in AD-related pathways 122
[21]. 123
However, the development of flavonoids as ther- 124
apeutic interventions for AD has been hindered by 125
considerable uncertainty surrounding bioavailabil- 126
ity, metabolism and basic pharmacokinetics. In this 127
review emerging mechanistic evidence for flavonoid- 128
mediated modulation of AD pathways is evaluated, 129
with a focus on studies where genuine consideration 130
has been given to the bioavailability of flavonoids. 131
The metabolism and bioavailability of flavonoids 132
in both humans and animal models, including the 133
increasingly evident role of the gut-microbiome 134
to these outcomes will be highlighted. Consider- 135
ing this, approaches to improve the translatability 136
of flavonoids into therapeutics for AD will be 137
discussed. Finally, we will examine whether supple- 138
ment or more conventional drug design approaches 139
based on flavonoid scaffolds represents the best way 140
forward. 141
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Fig. 1. Flavonoids can act as multi-modal inhibitors of AD pathology. (A) APP is processed in two pathways. In the non-amyloidogenic
pathway, APP is cleaved by -secretase (ADAM10) to produce -C-terminal fragment (-CTF) and secretory APP (sAPP) whereas the
pro-amyloidogenic pathway involves cleavage of APP -secretase (BACE1) to produce -CTF and sAPP. -CTF and -CTF is then
cleaved by -secretase to release P3 and A, respectively, as well as the APP intracellular domain (AICD). Flavonoids have been shown to
inhibit -secretase processing as well as promoting -secretase processing. This causes a shift towards the non-amyloidogenic pathway and
reduces the levels of A produced. (B) A can self-aggregate to form oligomers and eventually amyloid plaques. Flavonoids may be able
to inhibit the formation of amyloid plaques by binding to A and inhibiting aggregation or promoting the formation of non-toxic off-target
oligomers. (C) Toxic A monomers and oligomers have been shown to induce microglial activation and proliferation. Animal models have
shown that flavonoid intervention can reduce the levels of gliosis in the brain. (D) Activated microglia secrete pro-inflammatory cytokines
such as IL-1 and IL-6. Several flavonoids have been shown to reduce the levels of these cytokines in vivo. (E) The microtubule (MT)
associated protein tau, which is predominantly located in the axon, is hyperphosphorylated in AD, perhaps as a result of pro-inflammatory
cytokine release. This causes the dissociation of tau from the microtubule and mislocalisation to the somatodendritic region. Flavonoids
can inhibit several kinases associated with tau phosphorylation, as well as attenuating the proinflammatory response. Therefore, flavonoids
have the potential to reduce tau phosphorylation. (F) Hyperphosphorylated tau can self-aggregate to form toxic oligomers and eventually
neurofibrillary tangles (NFT). There is evidence that flavonoids can bind to tau and inhibit its aggregation or promote the formation of
non-toxic oligomers. (G) Hyperphosphorylated tau can mislocalise to post-synaptic terminals. Synaptic tau and A can cause synaptic
dysfunction (H) and eventual synapse loss (I). Flavonoids have been shown to upregulate BDNF to promote adult hippocampal neurogenesis
and synaptogenesis. Upregulation of BDNF may, therefore, prevent the loss of synapses and the consequent loss of neurons (J).
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Fig. 2. The flavonoid backbone and the six main subgroups with examples from each.
INHIBITING AD PATHOLOGY WITH142
FLAVONOIDS: MECHANISMS OF143
ACTION144
There are a very large number of studies describ-145
ing protective effects of various polyphe ols against146
AD-relevant insults following their administration to147
cell lines but, unfortunately, we are unable to include148
them all here. Likewise, several studies show that149
flavonoids can act as acetylcholinesterase (AChE)150
inhibitors but, as AChE inhibitors are symptomatic151
interventions and not preventative or disease modi-152
fying, they will not be discussed here (for review see153
[22]). A major advance in the last decade has been 154
the investigation of flavonoids in mouse models of 155
AD. Here, the analysis of these in vivo studies will be 156
mainly limited to those that have employed an oral 157
route of polyphenol administration in drinking water 158
or food, as well as via oral gavage; a summary of the 159
outcomes of those studies that used oral methods of 160
delivery is shown in Table 1. The doses investigated 161
range from 1–500 mg/kg/day which in humans would 162
be equivalent to 0.07–35 g intake for a 70 kg adult. 163
While little is known about the exact binding partners 164
of most flavonoids, common molecular mechanisms 165
have emerged which impact on A and tau pathology, 166
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Table 1
A summary of the results of flavonoid interventions in AD mouse models. Only interventions that used an oral method of delivery such as in water, diet, oral gavage (O.g.) or intragastric
administration (I.g.) were included. The method of delivery was classified as ‘orally’ where further detail was not supplied. Treatment times of 28–30 days were rounded to 1 month. A decrease
in A pathology was classified as a decrease in the levels of soluble or insoluble A1–40 or A1–42, a reduction in visible A plaques or a shift in APP processing. A decrease in gliosis involved
decreased levels of microglia or astroglia. Pro-inflammatory markers included iNOS, COX2, NF-κB, TNF-, M-CSF ICAM-1, TLR4, NLRP3, IL-16, IL-1, IL-6, IL-17A, IL-12p70 and the
JAK2/STAT3 pathway. Oxidative stress markers included Nrf2, SOD1, GPx, GSH, H2O2, MDA, CAT or HO-1. Synaptic markers included PSD95, SNAP23, SNAP25, Arc, Homer, Synaptotagmin,
Synapsin, Spinophilin, Gephyrin, Synaptophysin and glutamatergic receptor subunits. Evidence for pro-survival/neurogenesis included increases in BDNF, activation of the TrkA pathway and
inhibition of p75NTR pathway as well as decreased neuronal apoptosis and corresponding markers such as caspase-3. Improvement in the Morris Water Maze was classed as a reduced escape
latency, an increased time spent in the target quadrant and an increase in the number of platform crossings. () A significant effect was found; (×)no significant effect was found; (–) this variable
was not investigated. * Oxidative stress was identified as a decrease in anti-oxidative enzymes
Flavonoid Mouse Model Concentration Duration Method ↓-Amyloid ↓p-Tau ↓Gliosis ↓Pro- ↓ Oxidative ↑ Synaptic ↑Pro-Survival Improved Reference
(mg/kg/day) of Pathology inflammatory stress Markers Neurogenesis performance
Delivery Markers on MWM
7,8-DHF 5XFAD 5 2–6 months Orally  – – – –    [23]
Tg2576 (APPswe) 7 9–10 months Water × – – – –    [77]
Apigenin APPswe/PS1dE0 40 (5 days a
week)
4–7 months O.g.  – – –  –   [24]
Baicalein APPswe/PS1dE9 40 5–7 months Water – – – – – – –  [25]
80   –  –  – 
Baicalin APPswe/PS1dE9 100 8–9 months
(sacrificed at
10months)
O.g. × –   – – – – [163]
ICR injected with
A42 into
hippocampus
30 2 weeks after
A42 injection
O.g. – – – – – – – × [238]
50 – – – – – – – × [78]
100 – –   – – – 
Cyanidin 3-O--
glucopyranoside
APPswe/PS1dE9 5 8–10 months O.g. – – – – – – –  [79])
Dihydromyricetin Tg-SwiDi 2 20–23 months Orally  – – – –  – – [26]
Diosmin 3xTg-AD 1 6–10 months Diet  – – – – – – – [27]
10  – – – – – – –
EGCG TgCRND8 (APP) 50 2–6 months Orally  – – – – – – – [28]
SAMP8 5 60 days I.g.  – – – – –   [29]
15  – – – – –  
APPswe/PS1dE9 2 12–13 months O.g.  – –  –  –  [30]
6  – –  –  – 
2 9–10 months Water  – – – – –   [31]
30 12–15 months O.g.  – –  *  –  [32]
40 3–6 months Water  –  – – – – – [33]
2 9–10 months I.g.  –   – – – – [34]
50 8–14 months Water  – – – – – – – [35])
(Continued)
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Table 1
(Continued)
Flavonoid Mouse Model Concentration Duration Method ↓-Amyloid ↓p-Tau ↓Gliosis ↓Pro- ↓ Oxidative ↑ Synaptic ↑Pro-Survival Improved Reference
(mg/kg/day) of Pathology inflammatory stress Markers Neurogenesis performance
Delivery Markers on MWM
IcrTacSam mice with
intracerebroventricu-
lar injection of
A42
1.5 3 weeks prior to
A
Water  – – – – –   [36]
3  – – – – –  
IcrTacSam mice with
daily i.p. injection of
LPS for 1 week
1.5 3 weeks prior to
LPS
Water – – – – – – –  [37]
3  –   – –  
Ts65Dn 30 5–6 months Water – – – – – – – × [239]
(–)-Epicatechin APPswe/PS1dE9 40 3–12 months Diet  –   – – – × [38]
50 8–12 months Water × – – –  –  × [131]
TASTPM
(APPswe/PS1
M146V)
15mg/day 21 Days from 7
months
Water  – – – – – – – [39]
Eriodictyol LPS injection for 10
days at day 35 of
Eriodictyol treatment
25 45 days from 3
months
I.g. – – –  – – –  [40]
50  – –  – – – 
100  –   – – – 
Fisetin huAPPswe/PS1dE9 25 3–9 months Diet  –  –   –  [41]
SAMP8 25 3–10 months Diet – –     – – [117]
Formononetin APPswe/PS1dE9 15 7–8 months I.g.  – –  – – –  [42]
Hesperetin C57BL.6N mice
with LPS injection
for 2 weeks by i.p.
50 5 weeks (3
weeks prior to
LPS)
O.g. – –   –    [118]
Hesperidin APPswe/PS1dE9 50 3–7 months Diet × – – – × – – × [43]
100  – – –  – – 
20 9–12 months I.g. – – – – – – –  [80]
40 – – – –  – – 
80 – – – – – – – 
APP/PS1–21 100 10 days from 5
months
O.g.  –  – – – – – [44]
Uncorrected Author Proof
K
.L.H
ole
a
nd
R.J
.W
illiam
s/Reducing
the
Risk
ofD
em
entia
w
ith
Flavonoids
7
Icariin APPswe/PS1dE9 30 10–14 months O.g.  – – – – – – – [45]
60  – – – – – – –
APP/PS1 60 4–12 months O.g.  – –  – – –  [46]
APP/PS1 60 9–12 months Orally  – – – – –   [47]
5XFAD 50mol/kg/day 8 days from 7–9
months
Orally – – – – – – –  [81]
APP/PS1–21 100 10 days from 5
months
O.g.  –   – – – – [48]
3xTg-AD 65 6–8 months Diet  – – – –  –  [49]
Tg2576 (APPswe) 60 9–12 months Orally  – – – – –  – [50]
APPV17I Tg 30mol/kg/day 4–10 months I.g.  – – – – – – × [51]
100mol/kg/day  – – – – – – 
Liquirigenin Tg2576 (APPswe) 3 10–13 months I.g. × – – – – – – × [52]
10  – – – – – – 
30  – – – – – – 
Myricetin Tg2576 (APPswe) 0.5% diet 5–14 months Diet  – – – – – – – [53]
Naringin APPswe/PS1dE9 50 3–7 months Diet – – – – – – – × [54]
100  – – × – – – 
50 – – – – – – – × [82]
100 – – – – – – – 
Pinocembrin APPswe/PS1dE9 40 (5 days a
week)
4–7 months O.g. × –   – – –  [83]
Puerarin APPswe/PS1dE9 30 8–9 months Orally × – – –  – –  [84]
Quercetin 5XFAD 500 2 –4 months O.g.  – – – – – –  [57]
Intracerebroventricular
injection of
aggregated A25–35
at 10 weeks
50 2 weeks (from
DPI 5)
Orally – – –   – – – [58]
APP/PS1 2mg/g diet 1–13 months Diet   – – – – –  [59]
1–9 months   – – – – – 
6–13 months × × – – – – – ×
Rutin A25–35 injected
into third ventricle of
ICR mice
100 2 weeks
(following A)
Orally – – – –  – –  [85]
APPswe/PS1dE9 100 8–9.5 months Orally  –    – –  [55]
Scutellarin APPswe/PS1dE9 50 9–12 months Diet  –   – – –  [56]
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neuroinflammation, oxidative stress and neurogene-167
sis (Fig. 1).168
Flavonoid inhibition of APP processing and Aβ169
deposition170
Several flavonoids have shown the capacity to ame-171
liorate A pathology, both in vitro and in vivo [23–59]172
(Table 1). This effect may come as a result of a shift173
towards the non-amyloidogenic processing pathway,174
enhanced degradation of A and inhibition of aggre-175
gation (Fig. 1A, B). The resultant effect is a net176
reduction in A42. A well-established example of177
flavonoid-mediated inhibition of APP processing is178
seen with epigallocatechin gallate (EGCG), a much179
studied catechin that is abundant in tea. EGCG has180
been shown in vitro to dose dependently increase the181
proportion of mature ADAM10 (mADAM10) rela-182
tive to pro-ADAM10, correlating with a shift towards183
non-amyloidogenic processing and a decrease in A184
production [60, 61]. The increase in proteolytically185
active mADAM10 by EGCG was found to occur186
through at least two pathways: oestrogen receptor187
 (ER)-mediated activation of the PI3K/Akt path-188
way, and activation of the pro-ADAM10 cleavage189
enzyme furin through a PI3K-independent mech-190
anism [62]. The finding that EGCG shifts APP191
processing towards the non-amyloidogenic pathway192
has been confirmed in vivo in several different mouse193
models of AD [32, 35–37]. Oral administration of194
EGCG was found to promote -secretase activity195
while down regulating - and -secretase activity,196
and as such decreased the levels of both soluble and197
insoluble A.198
Another example is that of the flavone baicalein,199
which increases non-amyloidogenic cleavage of200
APP while inhibiting pro-amyloidogenic cleavage201
through a GABAA receptor-dependent pathway [63].202
GABAA receptor activation has been shown pre-203
viously to promote non-amyloidogenic processing204
of APP [64]. Furthermore, baicalein may regulate205
GABAA receptor activation [65], potentially through206
inhibition of GABA transaminase which degrades207
GABA [66].208
Moreover, the modulation of APP processing by209
flavonoids is known to occur at very low concentra-210
tions that could potentially be found in the brain.211
For example, (–)-epicatechin ((–)-EC)inhibits-212
secretase dependent APP processing with a low IC50213
of 20.5 nM, which correlates with reduced A pathol-214
ogy in TASTPM mice treated with (–)-EC [39].215
Furthermore, both quercetin (100 nM) and quercetin-216
3-O--rutinoside (rutin) (50 nM, 100 nM) significantly 217
increased degradation of BACE1 in SH-SY5Y cells 218
over expressing APPs we [67]. These effects at low 219
concentrations enhance the likelihood that flavonoids 220
could modulate APP processing in vivo. 221
Another mechanism through which flavonoids 222
could decrease the levels of A in the brain is by 223
enhancing degradation of A. Neprilysin (NEP), a 224
zinc-metalloprotease, is an A-degrading enzyme 225
which is decreased in affected areas of the AD 226
brain [68]. EGCG (1–3 g/ml) increases NEP release 227
from astrocytes in an Akt/PI3K-dependent manner, 228
resulting in degradation of exogenous A [69]. Con- 229
sequently, intragastric administration of EGCG to 230
SAMP8 mice, a senescence model of AD, increased 231
NEP expression and reduced A level same lio rating 232
spatial learning [29]. Similarly, oral administration 233
of a combination of green tea catechins, including 234
EGCG, to a transgenic human APP over expression 235
mouse caused an increase in NEP levels, as well 236
as decreased Aand improved spatial learning [70]. 237
Hence, EGCG can promote the degradation of A, 238
as well as inhibiting production. 239
Alternatively, flavonoids have the potential to tar- 240
get A through direct binding and inhibition of 241
aggregation which has been demonstrated in vitro in 242
aggregation assays [71–76] (Fig. 1B). A limitation 243
of these studies is that they are typically under- 244
taken at high stoichiometric A-flavonoid ratios that 245
would not easily be achieved in vivo. Neverthe- 246
less, such in vitro aggregation assays are useful in 247
identifying flavonoid structures with anti-aggregative 248
properties that could be used as molecular scaffolds 249
for the design of therapeutics. Consideration of the 250
physiological stoichiometry, impact of the cellular 251
environment and posttranslational modifications of 252
the target protein will enhance the overall translata- 253
bility in vivo. 254
While in vivo experiments have shown that 255
flavonoid treatments reduce the levels of insoluble, 256
aggregated A, it is not yet possible to determine 257
whether this is due to direct flavonoid binding to 258
the target protein or interactions with other proteins 259
such as kinases, which modulate the tendency for 260
amyloidogenic proteins to aggregate. Likewise, it is 261
tempting to relate the changes in spatial learning 262
and memory observed in through flavonoid inter- 263
vention in APP-based models of AD[23–25,30–32, 264
36,41–43,46,49–53,54–59,77–85]to reductions in 265
A (Table 1). However, the behavioural recov- 266
ery observed could be due to recruitment of other 267
mechanisms, either downstream of A signalling 268
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or involved in physiological cognition, particularly269
as not all studies with reductions in A-pathology270
correlated with behavioural improvements [38, 51]271
and vice versa [77, 83, 84]. Indeed, there is evi-272
dence to suggest that flavonoids modulate other273
disease-associated mechanisms, therefore having the274
potential to act as multi-modal AD therapeutics.275
Flavonoid inhibition of tau phosphorylation and276
aggregation277
Tau is a microtubule-associated protein that, phys-278
iologically, binds to microtubules predominantly in279
axons [86, 87]. The primary function of tau is280
thought to be the stabilisation and organisation of281
microtubules, aiding in the transport of cargo to282
and from synapses. However, in AD, tau is hyper-283
phosphorylated [88, 89], and dissociates from the284
microtubule (Fig. 1E). Hyperphosphorylation of tau285
promotes its mislocalization to the somatodendritic286
region [86] (Fig. 1G) where it has been shown to287
impair nuclear import [90], and synaptic function [91]288
(Fig. 1H). Tau accumulation in the somatodendritic289
region has also been associated with local transla-290
tion of tau mRNA, which can be induced by A291
applicationvia a FYN/ERK/S6 pathway [92]. Hyper-292
phosphorylated tau also aggregates into oligomers,293
eventually forming insoluble straight/paired helical294
filaments and neurofibrillary tangles (NFT) which are295
one of the characteristic hallmarks of AD (Fig. 1F).296
Several kinases are thought to contribute to the hyper-297
phosphorylated state of tau in AD, especially the298
proline directed kinases; GSK-3 [93, 94], CDK5299
[95, 96] and members of the MAPK family [97].300
The reported activity of flavonoids within MAPK301
and other protein kinase signalling pathways raises302
the potential for flavonoids to modulate tau phos-303
phorylation, thereby impacting on the development304
of tau pathology. This is highlighted in Fig. 3,305
which demonstrates the extent to which flavonoids306
have the potential to influence tau phosphorylation307
[97–108].308
A number of studies have demonstrated a role for309
JNK in tau phosphorylation [110, 111], and inhibit-310
ing JNK in primary cortical neurons, a transgenic311
Amouse model and human fibroblasts derived from312
AD patients all showed a decrease in phosphorylation313
of tau at Ser202, Ser205 and Ser422 [108]. Several314
flavonoids have been shown to inhibit JNK activity315
in vitro [112–115], although not typically at concen-316
trations found in vivo. Despite this, there is evidence317
from animal models of AD that oral or intragastric318
flavonoid administration can inhibit the activity of 319
JNK [30, 40, 116–118]. 320
The MAPK member p38 kinase has also been 321
proposed to contribute to hyperphosphorylation of 322
tau both directly [119] and indirectly, for example 323
through activation of the CDK5 activator p35 [120] 324
(Fig. 3). As such, increased levels of p38 kinase 325
and CDK5 were found to correlate with tau hyper- 326
phosphorylation in a htau transgenic mouse model 327
[121]. Furthermore, both p38 kinase and JNK were 328
found associated with NFTs in AD brains [122] 329
and in a patient with P301L-associated FTDP-17 330
[123]. Moreover, as will be discussed later, several 331
lines of evidence suggest that neuroinflammation 332
inducesp38 kinase-dependent phosphorylation of tau 333
[120, 124–126]. However, despite evidence support- 334
ing p38 kinase-mediated phosphorylation of tau as 335
well as flavonoid interactions with p38 kinase [127] 336
and flavonoid modulation of p38 kinase activity in 337
a variety of systems [40, 128, 129], there have been 338
few attempts to directly link the two mechanisms. 339
For example, administration of proanthocyanidins by 340
oral gavage reduced lead-induced tau phosphoryla- 341
tion which correlated with levels of activated p38 342
kinase and JNK, but no direct association was made 343
[130] (Table 1). 344
An alternative mechanism for the inhibition of 345
tau phosphorylation by flavonoids is through acti- 346
vation of the PI3K/Akt pathway which inhibits the 347
key tau kinase GSK-3 (Fig. 3) by phosphoryla- 348
tion at Ser9. Delivery of naringin [54], hesperidin 349
[43, 80], EGCG [30], (–)-EC [131], and baicalin 350
[25] through oral routes to mouse models of AD 351
have all been found to inhibit GSK-3 phosphory- 352
lation at Ser9. Additionally, several in vitro and in 353
silico models have pointed towards direct inhibition 354
of GSK-3 by flavonoids. For example, crystal struc- 355
ture studies of GSK-3 in complex with the flavonol 356
morin revealed direct inhibition of GSK-3 through 357
interactions with the ATP binding pocket [132], 358
which correlates with studies demonstrating reduc- 359
tion in tau phosphorylation in 3×Tg mice carrying 360
mutations in APPswe, PS1 M146V and taup301L[133]. 361
Similarly in silico docking studies with quercetin and 362
other citrus flavonoids suggested direct interaction 363
with the GSK-3 active site and direct inhibition 364
was confirmed in vitro [124, 131]. Furthermore, 365
unlike other serine/threonine protein kinases, GSK- 366
3 phosphorylation prefers pre-phosphorylation 4 367
amino acids C-terminally to the target phospho- 368
rylation site [135–138]. This adds an additional 369
layer of regulation, as inhibition of other tau-kinases 370
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Fig. 3. Flavonoids can modulate kinases involved in the hyperphosphorylation of tau. (A) Tau contains an amino-terminal domain, a proline
rich region and microtubule binding repeats (R1–R4). The diagram highlights the identified phosphorylation sites on tau which have been
shown to be phosphorylated by kinases that can be modulated by flavonoids: GSK3, ERK2, CDK5, JNK, p38 and Akt [97–108]. (B) A
diagram explaining how flavonoids may attenuate tau phosphorylation by modulation of kinases.
can consequently inhibit GSK-3 phosphorylation371
of tau.372
The few studies that have looked to directly link373
flavonoid treatment with tau phosphorylation have374
shown promising results. Oral delivery of grape375
seed polyphenolic extract (GSPE), which ontains376
high concentrations of proanthocyanidins, particu-377
larly catechin and (–)-EC oligomers, has been shown378
to inhibit tau phosphorylation at several key sites,379
such as: Ser202/Ser205 (AT8), Ser396/Ser404 (PHF-380
1), Thr212/Ser214 (AT100) [139] and Thr181 [140].381
Alongside this, significant reductions in the presence382
of Sarcosyl-insoluble tau follow GSPE treatment,383
suggestive of a reduction in aggregation [139, 140].384
It has been suggested that the mechanism through385
which GSPE elicits these effects is primarily through 386
inhibition of ERK1/2, as GSPE treatment did not cor- 387
relate with inhibition of GSK3. A role for ERK1/2 388
in phosphorylation of tau in AD is supported by 389
in vitro studies and immunohistological analysis of 390
post-mortem brains [97, 141, 142]. 391
Therefore, several flavonoids have the capacity 392
to reduce tau phosphorylation, either through inhi- 393
bition of GSK-3 via activation of the PI3K/Akt 394
pathway or modulation of MAPKs that are capable 395
of phosphorylating tau directly (Fig. 3). However, 396
there is a clear lack of studies exploring the direct 397
link between flavonoid-mediated modulation of tau- 398
phosphorylating kinases and the phosphorylation 399
state of tau itself. As such, more studies are required 400
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to determine whether flavonoid-mediated inhibition401
of tau phosphorylation is achievable at the nanomo-402
lar concentrations that might be detected in brain. It403
will be essential to investigate this in order to deter-404
mine the full therapeutic potential of flavonoidsin AD405
prevention.406
Similar to A, flavonoids have also been suggested407
to inhibit tau aggregation (Fig. 1F). Flavanols are the408
predominant group associated with inhibition of tau409
aggregation, although the flavone baicalein has been410
shown to inhibit tau oligomerization, albeit with a rel-411
atively high IC50 (∼35M) [143]. GSPE inhibits tau412
aggregation of the 306VQIVYK311 hexapeptide [140,413
144], which is thought to be essential in aggrega-414
tion of full length tau [145] and destabilisestauopathy415
patient-derived fibrils [146]. Interestingly, the oxida-416
tion of (–)-EC by H2O2 has been shown to facilitate417
inhibition of tau aggregation [147]. Studies giv-418
ing more consideration to stoichiometric ratios have419
demonstrated that (–)-Epicatechin-3-gallate (ECG)420
inhibits tau aggregation with an IC50-of 1.8M [148]421
and EGCG inhibits the aggregation of a tau peptide422
at substoichiometric levels (0.1X) [149]. While more423
studies are needed to determine the impact of this424
inhibition of tau aggregation in a cellular context,425
these studies suggest that flavonoid-mediated inhi-426
bition of tau aggregation is a possible approach for427
reducing AD pathology.428
Flavonoids, therefore, have the potential to inter-429
fere in the pathological phosphorylation of tau, as430
well as in the formation of tau oligomers and NFTs.431
Considering that tau phosphorylation and aggre-432
gation occurs consequently to A pathology, and433
therefore, is a more tractable target for impairing AD434
progression, a reduction in tau pathology could sug-435
gest intervention is possible at MCI and later stages436
of disease.437
Flavonoid modulation of neuroinflammatory438
response in AD439
The role of neuroinflammation in the develop-440
ment and progression of AD has long been debated.441
However, astrogliosis, microgliosis and chronic442
inflammation are now well accepted pathological443
hallmarks of AD, alongside plaques and tangles444
[150]. Genome wide association studies (GWAS)445
[151] and transcriptomics [152, 153] have high-446
lighted the involvement of the innate immune system447
in AD. In particular microglia have been linked to A448
and tau spreading and propagation [154], synaptic449
phagocytosis [155–157], and the release of pro-450
inflammatory cytokines that promote AD pathology 451
[150, 158]. 452
An increasing number of studies have impli- 453
cated microglia as the missing link between A 454
accumulation and tau pathology (Fig. 1C). In trans- 455
genic mice expressing the P301S mutation associated 456
with frontotemporal dementia (FTD), microglial 457
activation and synapse loss occurred prior to develop- 458
ment of tau tangles [159]. Furthermore, suppression 459
of the immune response with FK506, reduced 460
tau pathologyand increased lifespan. Histological 461
analysis of post-mortem brain correlated increased 462
microglial activation with AD pathology, suggest- 463
ing that microglial activation occurred following 464
A plaque deposition but prior to NFT formation 465
[160]. Analysis of the transcriptional profile of APPs 466
we/PS1dE9 and Tau22 transgenic mouse models, 467
which exhibit amyloid and tau pathology respec- 468
tively found that while A pathology activated the 469
expression of several AD risk genes associated with 470
microglia, this did not occur in the tau transgenic 471
mouse [161]. Thus, providing further evidence that 472
microglial activation lies upstream of tau phosphory- 473
lation and downstream of A. Furthermore, silencing 474
genes associated with the microglial inflammasome 475
(Nlrp3–/– and Asc–/–) in the Tau22 transgenic mouse 476
model of tauopathy led to reduced tau phospho- 477
rylation and aggregation [162]. Significantly, this 478
pathway could be stimulated by A-fibrils and was 479
essential to A- associated induction of tau phos- 480
phorylation in Tau22 mice following hippocampal 481
injection of APP/PS1 brain homogenate [162]. This 482
work presents a possible timeline of AD pathology, 483
with A accumulation initiating activation of NLRP3 484
inflammasomes (Fig. 1C) in microglia, which conse- 485
quently cause release of IL-1 (Fig. 1D) and thus 486
triggers tau phosphorylation (Fig. 1E). As IL-1 487
release has been shown to cause tau phosphorylation 488
in a p38-MAPK-dependent manner [125, 126], this 489
presents an additional target for flavonoid interven- 490
tion. 491
A reduction in gliosis [33, 34, 37, 38, 40, 41, 492
44, 48, 55, 56, 59, 78, 83, 117, 118, 163] as well 493
as neuroinflammatory markers [25, 30, 32, 34, 37, 494
38, 40, 42, 46, 48, 55, 56, 58, 78, 83, 117, 118, 495
163] has been shown in many animal models of AD 496
orally administered with flavonoids (Table 1). Addi- 497
tionally, several flavonoids have been identified that 498
inhibit microglial activation and IL-1 release. The 499
isoflavone genistein reduced mRNA levels of IL-1 500
and TNF- through a G-protein coupled oestrogen 501
receptor (GPER)-dependent mechanism in primary 502
Un
co
rre
cte
d A
uth
or
 P
ro
of
12 K.L. Hole and R.J. Williams / Reducing the Risk of Dementia with Flavonoids
microglia and BV2 cells [164]. Pre-treatment with503
the flavanone pinocembrin inhibited LPS-induced504
activation of BV2 cells and consequent release of505
pro-inflammatory mediators including IL-1 [165].506
In vivo, intra-gastric administration of procyanidins507
reduced morphine-induced activation of NLRP3 and508
IL-1, likely through inhibition of p38 kinase [166].509
Furthermore, a number of in vivo studies of flavonoid510
intake in AD mouse models have shown a reduc-511
tion in IL-1 following oral or gastric administration512
of EGCG [32, 34], formononetin [42] and eriodic-513
tyol [40]. Alongside this, many studies have reported514
decreases in levels of activated microglia following515
flavonoid treatment [167]516
In addition to IL-1, other pro-inflammatory517
cytokines have been suggested to play a role in AD.518
Tumour necrosis factor- (TNF-), which can be519
reduced by flavonoids [167], has also been implicated520
in AD [168, 169]. TNF-, and to a lesser extent IL-1521
was found to upregulate -secretase cleavage of APP522
through a JNK-dependent pathway, albeit in stably523
transfected HEK293 cells [170]. Furthermore, IL-6,524
which has been shown to be down regulated following525
administration of baicalin [78], formononetin [42]526
and eriodictyol [40], induces AD-like phosphoryla-527
tion of tau in primary rat hippocampal neurons [120]528
(Fig. 1D). This phosphorylation was found to be due529
to activation of p38 kinase which caused upregulation530
of the CDK5 activator p35. Therefore, it is possible531
that flavonoid-induced down regulation of IL-6 in AD532
mouse models could reduce tau phosphorylation.533
Given the accumulating evidence linking534
microglial activation, pro-inflammatory cytokine535
release and tau phosphorylation, it would be of536
interest to determine whether flavonoid-mediated537
attenuation of the microglial responses correlates538
with decreased tau pathology.539
Flavonoid modulation of antioxidant responses540
in AD541
Flavonoids are generally known for their antioxi-542
dant capacity [171], which may have benefit in AD as543
oxidative stress has been implicated in neurodegen-544
eration [172]. Evidence from post-mortem studies on545
AD-brain shows that, relative to control brain, there546
is a net reduction in the ability to decrease H2O2547
levels and stimulate anti-oxidative stress pathways548
[173, 174]. H2O2 can act as a messenger molecule549
activating signalling pathways, such as MAPK[175,550
176], or react with metallic cations, such as Fe2+, to551
produce HO· [177] which can damage cellular com-552
ponents such as lipids and proteins. Imbalances in 553
brain-iron levels have been reported in AD [178–181] 554
and likely contribute to cognitive decline [182], sup- 555
porting the suggestion that oxidative stress promotes 556
AD pathology. Indeed, studies in transgenic APP/PS1 557
mice showed that increasing oxidative stress in the 558
brain through delivery of a pro-oxidant iron rich diet 559
increased the deposition of A [183]. 560
While flavonoids have the capacity to act directly 561
as reactive oxygen scavengers by donating hydrogen, 562
it is unlikely that this is the mechanism by which 563
theyelicit their antioxidant potential due to the low 564
circulating concentration of flavonoids in the brain 565
relative to better characterised ROS scavengers such 566
as ascorbic acid [184, 185]. Instead, it is most likely 567
that the mechanism through which flavonoids inhibit 568
oxidative stress is through modulation of intracellu- 569
lar pathways such as the MAPK pathway. The MAPK 570
pathway responds to changes in the cellular environ- 571
ment, such as oxidative stress, and transduces these 572
stimuli into cellular responses through phosphoryla- 573
tion or activation of transcription factors. Activation 574
of anti-apoptotic ERK1/2 and PI3K/AKT pathways, 575
and downregulation of pro-apoptotic JNK pathways 576
by flavonoids is neuroprotective against multiple 577
stressors including oxidative stress at both high [112, 578
186] and physiological concentrations [114, 128]. 579
Another mechanism through which flavonoids 580
could act as antioxidants is viaPI3K dependent 581
activation of the transcription factor Nuclear fac- 582
tor erythroid 2-related factor 2 (Nrf2). Activation 583
of anti-oxidant response element (ARE) by Nrf2 584
enhances the expression of antioxidant-related genes, 585
such as those involved in synthesis of several anti- 586
oxidative enzymes including glutathione peroxidase 587
(GPx), catalase (CAT), heme-oxygenase 1 (HO-1) 588
and superoxide dismutase (SOD) [187]. Flavonoids 589
have consistently been shown to activate Nrf2 in 590
non-neuronal cell lines [188–190]. Furthermore, 591
physiological levels of (–)-EC have been shown to 592
upregulate ARE activity in astrocytes in a PI3-K 593
dependent manner [191], which has been shown 594
to protect neurons against oxidative stress [192]. 595
Quercetin [193] and EGCG [194] have also been 596
found to promote Nrf2 signalling in primary neu- 597
rons, however, the effects at physiologically relevant 598
concentrations were not investigated and there is 599
uncertainty as to the extent to which Nrf2 is expressed 600
in mature neurons. 601
Oral ingestion, or intragastric administration, of 602
fisetin [41], hesperidin [43, 80], quercetin [58], rutin 603
[55, 85], apigenin [24], puerarin [84] or (–)-EC [131] 604
Un
co
rre
cte
d A
uth
or
 P
ro
of
K.L. Hole and R.J. Williams / Reducing the Risk of Dementia with Flavonoids 13
has been shown to reduce markers of oxidative stress605
in the brains of mouse models of AD (Table 1).606
This was demonstrated through increased activity of607
anti-oxidative enzymes such as GPx, CAT and SOD608
and a reduction in measurable H2O2, ROS and mal-609
ondialdehyde (MDA). Collectively this supports a610
PI3K/Akt/Nrf2/ARE mechanism for conferring neu-611
roprotection against oxidative stress by flavonoids612
which may be beneficial in ameliorating AD pathol-613
ogy.614
Flavonoids promote BDNF induced neurogenesis615
in AD616
Brain-derived neurotrophic factor (BDNF) is617
known to play an important role in neural develop-618
ment, differentiation and synaptic plasticity through619
binding to its receptor TrkB. BDNF levels are also620
known to be decreased in the AD brain relative to621
healthy controls [195–197]. Furthermore, decreased622
levels of BDNF have been linked to delta-secretase623
mediated cleavage of both A and tau and subsequent624
neurodegeneration [198, 199]. BDNF also plays an625
important role in neurogenesis. The existence of adult626
hippocampal neurogenesis (AHN) in humans has627
been highly contested through the years, yet new628
advances in tissue processing techniques have now629
confirmed AHN [200, 201]. Moreover, it has been630
shown that, while neurogenesis decreases with aging,631
this decline is greatly exaggerated in AD [200]. Tar-632
geting BDNF/TrkB signalling to promote synaptic633
plasticity and neurogenesis may in turn slow the dete-634
rioration of the learning and memory abilities of AD635
patients.636
There is evidence that flavonoids can promote637
BDNF/TrkB signalling and related downstream638
effects. Physiological concentrations of (–)-EC639
(100 nM) activate the cAMP response element bind-640
ing protein (CREB) and consequently upregulate641
levels of BDNFin primary cortical neurons [202].642
Both quercetin and (–)-EC have been shown to643
upregulate the expression levels of BDNF follow-644
ing oral administration to several rodent models of645
AD [131, 203–205]. Furthermore, oral delivery of646
7,8-dihydroxyflavone (7,8-DHF), a TrkB agonist, has647
been shown to enhance long term potentiation (LTP),648
reduce synaptic loss, and improve performance in the649
Morris water maze (MWM) in vivo [23, 77]. Along-650
side the increased levels of BDNF seen with quercetin651
treatment, increases in neural progenitor cells (NPCs)652
and neural stem cells (NSC) associated with neuro-653
genesishave also been shown [205].654
Given this evidence, flavonoid-induced upreg- 655
ulation of the BDNF/TrkB pathway to increase 656
neurogenesis and reduce synaptic loss is an additional 657
mechanism through which flavonoids may be able to 658
reduce AD pathology (Fig. 1I). 659
EMERGING CONSIDERATIONS FOR 660
FLAVONOID INTERVENTIONS IN AD 661
Given the low success rate for translating therapeu- 662
tics from in vivo animal studies to effective human 663
interventions for AD, it is becoming increasingly 664
important to ensure that the ‘translatability gap’ is 665
as small as possible. In this section we consider 666
emerging evidence as to the extent of metabolism 667
and bioavailability of flavonoids, and how this could 668
influence the interpretation of existing data and exper- 669
imental design moving forward. 670
Flavonoid metabolome and brain bioavailability 671
While the ‘key’ metabolites of several notable 672
flavonoids have been known for years, there is only 673
limited knowledge of the full metabolite profiles 674
and, more importantly for AD intervention, which 675
metabolites reach the brain. 676
In this respect, important advances in the field have 677
been the use of radio labelling to determine complete 678
flavonoid metabolomes. Such examples include iden- 679
tification of the anthocyanidincyanidin-3-glucoside 680
(C3G) metabolome in humans [206]as well as the 681
(–)-EC metabolome in both humans and rodents 682
[207, 208]. As a result, 24 C3G and >20 (–)-EC 683
metabolites have now been identified in humans. In 684
comparing these metabolomes, there are similarities 685
in the metabolites produced, such as the presence 686
of structurally related molecules which have been 687
glucuronidated, methylated or sulphated, as well as 688
structurally unrelated metabolites such as hippuric 689
acid. Both of these human studies found that the 690
flavonoid metabolites were much more abundant than 691
the parent flavonoid molecule, to the extent that 14C- 692
(–)-EC itself was undetectable in the plasma or urine. 693
Therefore, it is likely that the bioactivity in vivo 694
resides in one or more flavonoid-derived metabolites 695
rather than the parent flavonoid. This is important as 696
many in vitro experiments use only parent flavonoids 697
to determine mechanisms of action and itis unlikely 698
that these unmetabolized flavonoids will be available 699
in the brain at active concentrations. In relation to 700
(–)-EC, structurally related epicatechin metabolites 701
(SREM) are likely to be the predominant bioactive 702
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constituents in the human brain, given the absence of703
the parent (–)-EC molecule in human plasma [207].704
This corresponds with pharmacokinetic studies in705
rats which showed that chronic oral administration706
of (–)-EC and catechin (C) resulted in a combined707
concentration of ∼484 nM (–)-EC/C-glucuronides708
and methyl-(–)-EC/C-glucuronides, while unmetab-709
olized (–)-EC could only be found in trace amounts710
[209]. Despite this many in vitro studies focus on711
concentrations >10M. Flavonoids often exhibit712
biphasic responses, activating protein kinase sig-713
nalling pathways at low concentrations (nM) and714
inhibiting at high concentrations (M), or vice versa715
[39, 114, 193]. Therefore, it is possible that where716
flavonoids are shown to inhibit pro-AD pathways in717
vitro at high concentrations, in vivo at nanomolar718
concentrations they may elicit different effects.719
Considering this, metabolic profiles for other720
flavonoids considered as potential therapeutic inter-721
ventions for dementia should be established to aid722
mechanistic investigations. In order to determine723
bioavailability in the brain analysis of cerebral spinal724
fluid (CSF) could potentially be undertaken to con-725
firm the appearance of flavonoid-derived metabolites.726
Species differences in flavonoid metabolism limit727
translatability of in vitro and in vivo studies728
The metabolism of flavonoids is an important con-729
sideration when designing and interpreting animal730
studies. While there are plenty of studies on flavonoid731
metabolism in rodents, the information about human732
metabolism is lacking. As more information becomes733
available, it is becoming clear that there are key differ-734
ences in flavanol metabolism between species, which735
may further limit the translatability of in vivo studies.736
An example of this is the absence of (–)-EC-737
3’-O-glucuronide and (–)-EC-3’-sulfate, the main738
metabolites of (–)-EC found in plasma and urine of739
humans, in rats [185, 208]. It is, therefore, not pos-740
sible to determine the effect of these metabolites on741
the rodent brain through delivery of (–)-EC alone.742
Such investigations would require direct i.p. injec-743
tion of these metabolites or administration by osmotic744
mini-pump.745
Furthermore, as mentioned previously, (–)-EC was746
not identified in plasma or urine of humans [208],747
although it was in rats [207]. Likewise, C3G metabo-748
lites were found to be 42 fold more abundant than the749
parent C3G molecule in humans [206], whereas in750
mice the difference was only 6 fold [210]. Therefore,751
highlighting doubts about the contribution of unme-752
tabolized flavonoids in the human brain relative to the 753
rodent models used in pre-clinical trials. 754
Studies of key quercetin metabolites in gerbils, 755
mice and rats showed that there are species depen- 756
dent differences in the metabolism of quercetin [211]. 757
Given what we now know about (–)-EC metabolism, 758
it is likely that this would correlate with differences 759
in quercetin metabolism between humans and rodents 760
as well. Without knowing what flavonoid metabolites 761
are found in humans, and particularly in the brain, it is 762
hard to pre-determine if flavonoids would elicit ther- 763
apeutic benefit in humans, despite positive findings 764
in animal models (Table 1). 765
Harnessing metabolites for flavonoid 766
intervention studies for AD 767
Utilising the information now available about 768
the pharmacokinetics and bioavailability of (–)- 769
EC, Ottaviani et al. have identified a collection 770
of SREMs that have the potential to be utilised 771
as biomarkers for (–)-EC intake [212]. The lev- 772
els of (–)-EC-3’-glucuronide, (–)-EC-3’-sulfate and 773
3’-O-methyl-(–)-EC-5-sulfate, collectively termed 774
SREMB,- in the urine can be used to estimate the 775
amount of (–)-EC ingested 24 hours previously. The 776
standard practice for epidemiological studies inter- 777
ested in implications of dietary compounds on health 778
and disease is through self-reporting of subjects to 779
estimate consumption, which is inherently unreliable. 780
With biomarkers to assess the actual amounts of (–)- 781
EC in the diet, future epidemiological studies will be 782
able to investigate the effect of (–)-EC on AD with 783
greater accuracy and certainty. 784
The impact of the microbiome on flavonoid 785
metabolism and AD 786
It is now known that the gut-microbiome is 787
responsible for the generation of several flavonoid 788
metabolites [185, 206, 208, 213–216]. The micro- 789
biome can partake in the deglycosylation, ring fission 790
and reduction of flavonoids [215], with deglyco- 791
sylation being of particular importance, as this is 792
thought to be essential for flavonoid absorption 793
[217], with the exception of C3G [218]. Despite 794
making up a large proportion of circulating flavonoid- 795
derived metabolites, few studies to date have explored 796
the mechanistic function of microbiome-derived 797
metabolites in relation to AD. An example of 798
such biologically relevant metabolites are phenyl- 799
-valerolactones and phenyl--valeric acids, formed 800
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from microbiome metabolism of flavanols. In vitro801
assays have suggested that these metabolites can per-802
meate the blood brain barrier (BBB) [219] and reduce803
A-toxicity [220].There is further suggestion that 3-804
HBA and 3-HPP, derived from GSPE metabolism by805
the rat microbiome, can impair the aggregation of806
A peptides, nonetheless at high molar ratios [213].807
Other studies in SHSY-5Y cells show some ability808
of microbiome-derived metabolites of flavanols to809
act in a neuroprotective manner against H2O2 treat-810
ment and SIN-1-induced stress [221, 222]. There is811
recent evidence that flavonoid intake can alter the812
composition of the human gut microbiome [223].813
However, it is yet to be determined what effect, if814
any, this may have on health and disease. An increas-815
ing number of studies have suggested a role for the816
gut microbiome in AD, most likely through modula-817
tion of microglial activation. One study in cognitively818
impaired elderly found a significant increase in819
abundance of pro-inflammatory bacteria as well as820
decreased abundance of anti-inflammatory bacteria821
in the gut of A positive relative to A-negative822
participants [224]. Similarly, it was also found that823
AD patients have a distinct gut-microbiome com-824
position relative to age and sex-matched controls825
[225]. Likewise, 5XFAD mice exhibited a different826
microbiome composition relative to non-transgenic827
controls and this dysbiosis was suggested to pro-828
mote microglial activation [226]. By treating these829
mice with GV-971, which promotes normal gut-830
microbiome composition, A, tau and behavioural831
pathology was significantly reduced. Interestingly,832
the treatment of APPPS1-21 mice with antibiotics833
led to a reduction in A and microglial pathology in834
male, but not female, mice, suggesting a sex-specific835
role for the microbiome in AD [227]. Therefore, mod-836
ulation of the microbiome composition by flavonoids837
should be considered carefully as this has potential838
to promote or hinder AD progression.839
Furthermore, there are important inter-individual840
differences in the composition of the gut microbiome841
as a result of various factors including age, sex, drug842
use and dietary intake [228]. This is significant as843
the composition of the human gut microbiome has so844
far been shown to alter the metabolism of flavonols845
[229, 230] and isoflavones [215]. Therefore, it may846
become beneficial to assess the microbiome of an847
individual before recommending flavonoid interven-848
tions in order to personalise the amount and type of849
flavonoids for maximum efficacy. Furthermore, com-850
bined treatment with pro-biotics might enhance the851
effects of flavonoid intake by ensuring the most effi-852
cient microbiota are present in the gut. Moreover, AD 853
risk factors such as diabetes and obesity also influ- 854
ence polyphenol uptake and metabolism [231, 232]. 855
Although this might not result from direct changes 856
to the microbiome, they could impair an individual’s 857
responsiveness to flavonoid intervention. 858
Moving forward therefore, the potential contri- 859
bution of the microbiome should be taken into 860
consideration when looking to assess the bioavail- 861
ability and efficacy of flavonoids or flavonoid-derived 862
drugs particularly when the method of flavonoid 863
delivery bypasses the gut and other key sites of 864
metabolism. 865
Alterations to Promotethe Stability, 866
Bioavailability, Specificity and Activity of 867
Flavonoids 868
Like many small molecule and antibody thera- 869
pies, several flavonoids are likely to exhibit low 870
brain bioavailability, a potential limitation of their 871
use as therapeutic interventions in humans[233]. 872
One method to overcome this is to encapsulate the 873
flavonoids in nanoparticles. This increases their sta- 874
bility and brain bioavailability as well as promoting 875
sustained release [234]. Furthermore, nanoparticles 876
can include targeting peptides in their coating, 877
allowing for more specific activity. As a result, nano- 878
encapsulation could reduce the quantity of flavonoid 879
that would need to be administered. 880
Nano-encapsulation of EGCG improved bio 881
availability in rats as well as its -secretase promot- 882
ing activity in SHSY-5Y cells [235]. Furthermore, 883
nanoparticles loaded with EGCG and ascorbic acid 884
were found to decrease A deposition and increase 885
synaptic expression relative to EGCG alone in 886
APP/PS1 mice, which correlated with improved spa- 887
tial learning [33]. However, it is unclear whether this 888
is a result of the nanoparticles or the added ascorbic 889
acid, which is a powerful antioxidant. It should also 890
be noted that this study found that the nanoparticles 891
may disrupt the BBB, which needs to be investigated 892
further in vivo [33]. Nano-encapsulation of quercetin 893
also showed significant improvements to cognition 894
and memory in SAMP8 mice as well as lower levels 895
of markers of inflammation relative to free quercetin 896
[236]. These results were in-line with increased 897
quercetin levels in the brain (∼200 ng/g free 898
quercetin: 371 ng/g nano-encapsulated quercetin). 899
Therefore, nano-encapsulating flavonoids may 900
improve their efficacy in vivo, thus making them 901
more appealing as therapeutic interventions for AD. 902
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Their capacity to act at multiple targets associ-903
ated with AD pathology makes flavonoids attractive904
molecular scaffolds for development of more potent905
inhibitors of AD pathology. Alteration of the906
flavonoid structure has been found to enhance907
inhibitionofBACE-1, A aggregation and acetyl-908
cholinesterase (AChE) activity, as reviewed by909
Jalili-Baleh (2018) [237]. However, it is possible that910
these changes will impact the ability of the flavonoid-911
based drug to reach the brain.912
While the development of more potent and specific913
flavonoid-derived therapeutics has the potential to914
elicit stronger effects, the switch from nutraceutical to915
pharmaceutical brings its own hurdles. The increased916
expense and potency could mean that these com-917
pounds are no longer suitable for early and sustained918
delivery throughout midlife. In contrast, supplemen-919
tation with naturally available flavonoids is likely to920
be more widely accessible, with potentially fewer921
side effects. As such, even if direct modulation of AD922
pathways is weaker, capacity for long term delivery923
could contribute to an overall benefit.924
Incorporating the Metabolome to Promote925
Translatability in Identifying a Therapeutic926
Intervention for AD927
The identification of the (–)-EC metabolome928
yielded a library of potential bioactive molecules, ret-929
rospective biomarkers of (–)-EC intake, and a greater930
understanding of the limitations of the animal models931
used. In the future, it would be of great value to eluci-932
date the full human metabolomes of more flavonoids933
in order to limit the risk of failure at clinical trials.934
Utilising techniques such as the radiolabelling used935
by Czank et al. (2013) and Ottaviani et al. (2016) to936
identify the full human metabolome of these clin-937
ically relevant flavonoids may help to bridge the938
translatability gap between pre-clinical investigations939
and human interventions.940
An important point to consider is that despite941
considerable uncertainty that parent flavonoids are942
present at sufficient concentrations in the brain, the943
metabolites themselves likely have poor bioavail-944
ability following oral delivery. To overcome this,945
one route would be to nano-encapsulate the metabo-946
lite of interest, thus improving its bioavailability.947
Alternatively, it may be more efficient to use the948
parent-flavonoid as a pro-drug, which with appropri-949
ate dosing will facilitate availability of metabolites950
in the brain. In this scenario, it will be necessary951
to investigate the mechanistic effects of combina-952
tions of metabolites that derive from the same parent 953
flavonoid, to ensure a consistent mechanism of action. 954
While the incorporation of metabolism and brain 955
bioavailability creates additional hurdles in exper- 956
imental design, it also increases the likelihood 957
of accurately identifying bioactive flavonoids or 958
flavonoid-derived metabolites that can be used as 959
therapeutic interventions for AD in humans. 960
CONCLUSIONS 961
As this review has highlighted, flavonoids have the 962
potential to act as multimodal therapeutics to pre- 963
vent the onset and/or progression of AD. Much of the 964
research effort to date has focused on the reduction of 965
A by flavonoids. The advantage of flavonoids over 966
conventional A-targeting drugs such as antibodies 967
and small molecule inhibitors is that it is possible 968
for them to be administered as dietary supplements. 969
Due to their relative aff rdability and low toxicity, 970
supplementation with flavonoids could enable early 971
protection at a young age and throughout life, without 972
the need for pre-clinical diagnosis. However, deter- 973
mining if early and consistent flavonoid intake is 974
capable of preventing AD onset would require an 975
enormous amount of resource and most importantly, 976
time. Until it is possible to accurately identify AD 977
pre-symptomatically, before A accumulation has 978
initiated downstream toxic cascades, it may be nec- 979
essary to shift the focus to flavonoid induced changes 980
to later-onset pathologies such as neuroinflamma- 981
tion or tau phosphorylation. To date, tau pathology 982
is clearly underrepresented in flavonoid-intervention 983
studies carried out in mouse models of AD despite 984
the strong basis for flavonoid-modulation of tau phos- 985
phorylating kinases. 986
Moving forward, it will be important to incorporate 987
the bioavailability and metabolism into experimen- 988
tal planning throughout all stages of pre-clinical 989
research. To reduce the current translatability gap, 990
it will be essential to: 991
1. Focus on physiologically relevant concen- 992
trations when determining the mechanistic 993
functions of flavonoids in vitro, to ensure that 994
said mechanisms are possible in vivo. 995
2. Identify the complete human metabolomes of 996
flavonoids of interest to determine functional 997
metabolites. 998
3. Compare the mechanisms of action of parent 999
flavonoids with their human metabolites, both 1000
alone and in combination, to ensure that the 1001
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same mechanisms will be engaged following in1002
vivo administration.1003
Taking this into consideration should result in more1004
efficient and effective identification of flavonoid-1005
based molecules that could succeed as therapeutic1006
interventions for AD.1007
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